ClinicalTrials.gg
RecruitingNCT06226025Updated May 11, 2026

Correcting Circadian Rhythms to Breakthrough in Bipolar Disorder

A Phase 2 interventional study of Melatonin and Placebo in Bipolar Disorder and Delayed Sleep-Wake Phase Disorder, sponsored by Leslie Swanson. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Leslie Swanson · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 836 studies in Bipolar Disorder with a site in United States — 77 open to participants now, 96 under way, 8 of them phase 3. Bipolar Disorder · United States.

Planned enrollment
378th of 703
50 · median 58
Started
2024
with 33 others
Phase 2
92 of 836
9 open now
Primary completion
2026-12
later than 18 of 94 live
Registered
766th of 836
by date

Among the 836 studies in Bipolar Disorder with a site in United States, this one is the 378th largest by planned enrollment of the 703 interventional ones that give a count, is one of 34 that started in 2024, is one of 92 in phase 2, reaches primary completion later than 18 of the 94 other live ones, and was the 766th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

77 of the 836 studies in Bipolar Disorder with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 836 studies in Bipolar Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to test whether a dietary supplement (low-dose melatonin) commonly used to treat night owls, administered in conjunction with a behavioral sleep intervention, will help to shift the brain clock earlier and improve mood and sleep in bipolar disorder. Eligible participants will be randomized to receive melatonin plus a behavioral sleep intervention or placebo plus a behavioral sleep placebo.

The hypotheses for this study include:

  • Melatonin plus behavioral sleep intervention (compared to placebo plus behavioral sleep placebo) will produce a greater advance of dim light melatonin onset (DLMO), between pre- and post-treatment.
  • Melatonin (compared to placebo) will produce a greater reduction in Patient Health Questionnaire-9 score between pre- and post-treatment.
03

Conditions studied

  • Bipolar Disorder
  • Delayed Sleep-Wake Phase Disorder

Keywords

  • Correcting Circadian Rhythms
  • Melatonin
  • Placebo
  • Dim light melatonin onset
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving
  • Meet The (DSM) criteria for bipolar disorder (BD) I or II
  • Evening chronotype per the Morningness-Eveningness Questionnaire (MEQ) defined by a score of \<42
  • At least mild depressive symptoms on the Patient Health Questionnaire (PHQ)-9 defined by a score ≥5
  • Psychotropic medications at stable dose for past month
  • Able to download the MyDataHelps mobile application (app), and open app on participants' own phone
  • Willing to abstain from alcohol for the duration of the intervention phase
  • Female participants of (i.e., patients are not permanently sterilized (hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) or (12 months with no menses without an alternative medical cause) by report) must agree to use a reliable method of from the screening visit until 4 weeks after the study has completed.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of, or high risk for, a sleep disorder other than DSPD per interview and medical record review (when available) including:

    • Insomnia per
    • Sleep-disordered breathing per Snoring, tiredness, observed apnea, blood pressure, , age, neck circumference, and gender (STOP-BANG)
    • Restless leg syndrome per sleep interview
    • Narcolepsy
    • Suspicion of vasomotor symptoms impacting sleep per interview for women that may be perimenopausal or .
  • Risk of current mania (per Young Mania Rating Scale (YMRS) score > 19).
  • Suicidal or at high risk for suicide per Columbia Suicide Severity Rating Scale (C-SSRS) guidelines (i.e., presence of any suicidal behavior-suicide attempt, interrupted attempt, abort attempt, or preparatory behavior-in the past 3 months; and/or current active suicidal ideation with any intent), or as determined by the principal investigators.
  • Presence of cardiac implantable electronic device, such as defibrillator or pacemaker.
  • Presence of chronic psychiatric conditions which may directly influence sleep per interview and medical record review (when available), including:

    • Current illicit drug use per the Drug Use Disorders Identification Test (DUDIT) defined by a score of ≥ 25
    • Current alcohol or drug abuse per the Alcohol Use Disorder Identification Test (AUDIT) defined by a score of ≥ 16 and DUDIT
    • Currently experiencing psychosis
  • Presence of unstable chronic medical condition which may directly influence sleep:

    • Chronic pain
    • Thyroid conditions
  • Current or history of medical conditions which may be affected by melatonin per self-report and medical record review (when available), such as:

    • Hypertension or hypotension
    • Diabetes Type 1 or Type 2
    • Clotting/bleeding disorders
    • Epilepsy/seizures
    • disorders
    • Conditions requiring management such as transplant
  • Per self-report or medical record review (when available), current use of medications which may have interactions with melatonin (see protocol for more details).
  • Current use of medications that may interfere with the measurement of melatonin (non-steroidal anti-inflammatory drugs if used daily, and beta-blockers), per self-report and medical record review (when available).
  • Self-report use of melatonin in the past month.
  • to melatonin or any other component of the melatonin or placebo product.
  • Pregnancy (as determined by dipstick urinary pregnancy test at screening for women of ) or self-report of breastfeeding and/or plan to become pregnant in the next 3 months.
  • Self-report of routine night shift work.
  • Self-report of past month travel or planned travel during the study across more than one time zone.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Melatonin

    Oral medication will be taken for 28 days on the afternoon or evening of the participants first intervention session and continue daily for the remainder of the treatment period.

    Drug: Melatonin · Behavioral: Behavioral sleep intervention

  • Placebo comparator
    Placebo

    Oral medication will be taken for 28 days on the afternoon or evening of the participants first intervention session and continue daily for the remainder of the treatment period.

    Other: Placebo · Behavioral: Behavioral sleep control

Interventions

  • Participants randomized to this intervention will take 1 oral pill (0.5 milligrams (mg)) daily. They will attend 4 weekly behavioral sleep intervention sessions with a therapist. In addition, participants will complete questionnaires (MyDataHelp app), monitor sleep, collect saliva samples, and wear the Fitbit Device.

  • OtherPlacebo

    Participants randomized to this intervention will take 1 oral placebo pill daily. They will attend 4 weekly behavioral sleep control sessions with a therapist. In addition, participants will complete questionnaires (MyDataHelp app), monitor sleep, collect saliva samples, and wear the Fitbit Device.

  • BehavioralBehavioral sleep intervention

    An active intervention that is typically paired with melatonin to maximize treatment effects.

  • BehavioralBehavioral sleep control

    A behavioral placebo (which does not improve sleep in delayed sleep-wake phase disorder) to control for social/interpersonal effects of behavioral sleep intervention sessions.

06

What researchers measure

Primary outcomes

  1. Change in time of Dim Light Melatonin Onset (DLMO) baseline (pre-treatment) to 4 weeks (post-treatment)

    Onset of melatonin in dim light conditions as measured in saliva (also called DLMO). Time of DLMO is measured in clock time and change in time of DLMO is measured in hours. The change score is calculated as time at 4 weeks minus baseline time. Thus, positive scores indicate a shift towards a later onset of melatonin and negative scores indicate a shift towards an earlier onset of melatonin.

    Time frame: 4 weeks (after treatment period)

Secondary outcomes

  1. Change in the Patient Health Questionnaire-9 (PHQ-9)

    The PHQ-9 is a 9-item self-report scale to screen for symptoms of depression. Items are rated on a 4-point Likert scale from 0 (not at all) to 3 (nearly every day), with total scores ranging from 0 to 27, where higher scores indicate more severe depressive symptoms.

    Time frame: Baseline, 4 weeks (after treatment period)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Additional data collected as part of the study's fundings requirements per the National Institute of Mental Health to be shared to the National Institute of Mental Health Data Archive include the Generalized Anxiety-Disorder 7 item scale; World Health Organization Disability Assessment Schedule 2.0 scale, and the DSM-5 cross cutting assessment. Under the current protocol these data are to be collected to fulfill the National Institute of Mental Health funding requirements but are not included as endpoints or in our analytic plan.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 42 non-industry phase 2 interventional studies under Bipolar Disorder, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's planned 28 months is below that.

Counting every sponsor, half of 56 studies reached it within 33 months; a quarter within 20 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2024
First posted
Jan 26, 2024
StartActual
Aug 13, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06226025
Lead sponsor
Leslie Swanson
Responsible party
Leslie Swanson (Associate Professor of Psychiatry, University of Michigan) — Sponsor-investigator
First posted
Jan 26, 2024
Start date
Aug 13, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 11, 2026

Study contacts

Kelley DuBuc
Contact
dubuck@umich.edu
734-764-2256
Leslie Swanson, PhD
principal investigator · University of Michigan

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Melatonin

Start the discussion